| scholarly article | Q13442814 |
| P2093 | author name string | Rong Zheng | |
| Yong Huang | |||
| Jian He | |||
| Duo Zheng | |||
| Guoqing Zhang | |||
| Jie Tan | |||
| Nuo Yang | |||
| Sufang Zhou | |||
| Xiaoling Lu | |||
| Yongxiang Zhao | |||
| Zhenghua Zhang | |||
| Jieping Li | |||
| Zongqiang Lai | |||
| Xinglu Jiang | |||
| Chaofan Zhou | |||
| Lige Wu | |||
| Qianyi Sun | |||
| P2860 | cites work | Tumor-dendritic cell fusion technology and immunotherapy strategies | Q73665608 |
| Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity | Q74027305 | ||
| Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells | Q74310288 | ||
| Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells | Q81245689 | ||
| Acid-sensing ion channels contribute to the effect of acidosis on the function of dendritic cells | Q83411235 | ||
| Type I collagen promotes epithelial-mesenchymal transition through ILK-dependent activation of NF-kappaB and LEF-1 | Q22254808 | ||
| Dendritic-Tumor Fusion Cell-Based Cancer Vaccines | Q26744827 | ||
| Metabolic influences that regulate dendritic cell function in tumors | Q27011306 | ||
| Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy | Q28005535 | ||
| Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected | Q28084627 | ||
| Regulatory T cells and immune tolerance | Q29616864 | ||
| A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice | Q33671350 | ||
| Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma | Q33732491 | ||
| Metabolite extraction from suspension-cultured mammalian cells for global metabolite profiling | Q33974831 | ||
| Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth | Q34289902 | ||
| Collagen-receptor signaling in health and disease | Q34432970 | ||
| Collagens—structure, function, and biosynthesis | Q35586683 | ||
| Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. | Q36246932 | ||
| Dendritic cell-Ewing's sarcoma cell hybrids enhance antitumor immunity | Q36803613 | ||
| Cancer Prevention: Obstacles, Challenges and the Road Ahead. | Q37002946 | ||
| Cancer immunotherapy by dendritic cells | Q37272237 | ||
| Cancer vaccine by fusions of dendritic and cancer cells | Q37698219 | ||
| Cancer immunotherapy by fusions of dendritic cells and tumor cells | Q37773276 | ||
| Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? | Q37973820 | ||
| The Human Vaccines Project: A roadmap for cancer vaccine development | Q38807692 | ||
| Dendritic cells: In vitro culture in two- and three-dimensional collagen systems and expression of collagen receptors in tumors and atherosclerotic microenvironments. | Q39020907 | ||
| Characterization of structure and direct antigen presentation by dendritic/tumor-fused cells as cancer vaccines | Q39197581 | ||
| Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist | Q39582908 | ||
| Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. | Q40468313 | ||
| Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study | Q40591057 | ||
| Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions | Q42711605 | ||
| Collagen induces maturation of human monocyte-derived dendritic cells by signaling through osteoclast-associated receptor | Q43195283 | ||
| An optimized buffer system for NMR-based urinary metabonomics with effective pH control, chemical shift consistency and dilution minimization | Q46043421 | ||
| Effective quenching processes for physiologically valid metabolite profiling of suspension cultured Mammalian cells | Q46211106 | ||
| Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma | Q46586294 | ||
| Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. | Q50858761 | ||
| Acidosis improves uptake of antigens and MHC class I-restricted presentation by dendritic cells. | Q51024730 | ||
| Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. | Q52944980 | ||
| Cancer immunotherapy: dendritic-cell vaccines on the move. | Q52959842 | ||
| The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells | Q56904544 | ||
| Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells | Q73321311 | ||
| P433 | issue | 12 | |
| P304 | page(s) | e1361094 | |
| P577 | publication date | 2017-08-08 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells | |
| P478 | volume | 6 |
| Q91129601 | Novel fusion cells derived from tumor cells expressing the heterologous α-galactose epitope and dendritic cells effectively target cancer | cites work | P2860 |
Search more.